The declining but divided fight against genital organ neoplasms: Who is still left behind?

S Shrishti Sinha (6Richmond University Medical center, Staten Island, United States) M Mian Zahid Jan Kakakhel (Rehman Medical College, Peshawar, Pakistan) M Mishaal Munir (5Lahore Medical and Dental College, Lahore, Pakistan) H Husnain Ahmad (Shalamar Medical and Dental College, Lahore, Pakistan) I Iqra Khan (Services Institue of Medical Sciences, Lahore, Pakistan) M Mahnoor Asghar Keen (4Khyber Medical College, Peshawar, Pakistan) T Tehreem Asghar (Akhtar Saeed Medical College, Lahore, Punjab, Pakistan) U Usama Idrees (Khawaja Corporation, Sialkot, Pakistan) H Hamna Jawad (Rehman Medical College, Peshawar, Pakistan) Z Zayna Rehman (Pakistan Health Research Council - Khyber Medical College, Peshawar, Pakistan) B Barkah Ali (Dow University of Health Sciences, Karachi, Pakistan) A Anum Zia Khan (Jinnah Medical and Dental College, Sindh, Pakistan) W Wissal Fatih (CHU Mohamed VI, Cadi Ayad University, Marrakech, Morocco) P Pranjal Singh (Kirori Mal College, Delhi University, Delhi, India) J jibran Ikram (Pak International Medical College, Peshawar, Pakistan) A Asfand Yar Cheema (1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States)

Abstract

e17003 Background: Genital organ neoplasms contribute to cancer deaths, with gender-based differences in incidence and outcomes. Despite treatment advances, mortality remains high, influenced by age, gender, healthcare access, and region. Using CDC WONDER data, this study analyzes mortality trends in adults 25 and older, providing insights for targeted health strategies. Methods: Using data from the CDC WONDER database, we calculated the crude and age-adjusted mortality rates (AAMRs) per 1,000,000 individuals (≥25 years) and used Joinpoint regression to determine annual and average annual percent change (AAPC) in the mortality trends. Results: Between 1999 and 2022, 1,817,018 deaths from genital organ neoplasms were reported in the US, with 1,043,269 in males and 773,749 in females. Overall AAMR declined from 261.9 to 182.7 in males and from 162.8 to 136.8 in females per 1,000,000. When comparing across racial groups, NH Black or African American males had the highest AAMR at 363.4, followed by NH White males (190.3), NH American Indians or Alaska Natives (165.9), Hispanics or Latinos (149.3) and NH Asians or Pacific Islanders (85.4). Similarly, NH Black or African American females had the highest AAMR at 194.9, followed by NH White females (145.4), NH American Indians or Alaska Natives (117), Hispanics or Latinos (116.2) and NH Asians or Pacific Islanders (91.6). Males with genital neoplasms had AAMR as follows: West (207.7), Midwest (203.6), South (196.5) and Northeast (189.7). In comparison, females with genital neoplasms had AAMR: Northeast (155.5), Midwest (151.4), South (142) and West (138.6). Age groups 65-85+ had the highest CMR in both sexes. The highest number of deaths occurred in the decedent's home, with males accounting for 370,868 and females 280,210 deaths. Conclusions: Mortality from genital organ neoplasms has decreased overall, with males showing higher AAMR than females. NH Black or African American individuals have the highest mortality rates across both genders. Regional disparities emphasize the need for region-specific healthcare strategies. Targeted interventions are crucial to improve outcomes and ensure equitable care access. Deaths and AAMRs per 1,000,000 for male vs female genital organ neoplasms among (1999-2022). Variable Males Females Deaths (n) AAMR (95% CI) Deaths (n) AAMR (95% CI) NH American Indians 3,683 165.9 (160.4 to 171.5) 3,300 115.2 (99 to 131.4) NH Asians 14,042 85.4 (84 to 86.9) 18,628 91.6 (90.3 to 93) NH Blacks 146,257 363.4 (361.5 to 365.3) 89,384 194.9 (193.6 to 196.2) NH White 729,358 190.3 (189.9 to 190.8) 538,911 145.4 (145 to 145.8) Hispanics 47,782 149.3 (148 to 150.7) 4,7,90 116.2 (115.1 to 117.3) Northeast 179,914 189.7 (188.8 to 190.6) 144,414 155.5 (154.7 to 156.3) Midwest 219,600 203.6 (202.7 to 204.4) 161,964 151.4 (150.6 to 152.1) South 335,566 196.5 (195.8 to 197.1) 248,760 142 (141.4 to 142.5) West 208,111 207.7 (206.8 to 208.6) 143,942 138.6 (137.9 to 139.3)

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (16)

S

Shrishti Sinha

6Richmond University Medical center, Staten Island, United States

M

Mian Zahid Jan Kakakhel

Rehman Medical College, Peshawar, Pakistan

M

Mishaal Munir

5Lahore Medical and Dental College, Lahore, Pakistan

H

Husnain Ahmad

Shalamar Medical and Dental College, Lahore, Pakistan

I

Iqra Khan

Services Institue of Medical Sciences, Lahore, Pakistan

M

Mahnoor Asghar Keen

4Khyber Medical College, Peshawar, Pakistan

T

Tehreem Asghar

Akhtar Saeed Medical College, Lahore, Punjab, Pakistan

U

Usama Idrees

Khawaja Corporation, Sialkot, Pakistan

H

Hamna Jawad

Rehman Medical College, Peshawar, Pakistan

Z

Zayna Rehman

Pakistan Health Research Council - Khyber Medical College, Peshawar, Pakistan

B

Barkah Ali

Dow University of Health Sciences, Karachi, Pakistan

A

Anum Zia Khan

Jinnah Medical and Dental College, Sindh, Pakistan

W

Wissal Fatih

CHU Mohamed VI, Cadi Ayad University, Marrakech, Morocco

P

Pranjal Singh

Kirori Mal College, Delhi University, Delhi, India

J

jibran Ikram

Pak International Medical College, Peshawar, Pakistan

A

Asfand Yar Cheema

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States